#Israel #Rehovot #Evogene #PCSK9 #ELEO

Innovative Collaboration between Evogene and ELEO

In a significant move towards the advancement of cardiovascular therapies, Evogene Ltd. and ELEO Inc. have announced a strategic partnership aimed at developing groundbreaking oral small-molecule inhibitors targeting the PCSK9 pathway. This collaboration merges Evogene’s expertise in computational chemistry with ELEO’s proven proficiency in biopharmaceutical development, presenting exciting prospects for addressing hyperlipidemia and related cardiovascular diseases.

The Cardiovascular Challenge

Cardiovascular diseases continue to be the world’s leading cause of death, with high levels of LDL cholesterol being a major modifiable risk factor. Currently available PCSK9 therapies have displayed impressive clinical results; however, their injectable nature and high costs present barriers to patient access. There's a growing demand for next-generation oral alternatives that offer enhanced potency, safety, and convenience.

Market analysts predict that the PCSK9 inhibitor market will grow from approximately $4.4 billion in 2025 to over $23 billion by 2035. This dramatic expansion highlights the immense opportunity that exists for new players in this vital therapeutic area.

Combining Strengths

Through their collaboration, Evogene and ELEO will strategize to leverage their complementary technologies. Evogene will utilize its innovative ChemPass AI™ platform, designed to enhance generative molecular design by optimizing small-molecule candidates based on parameters critical for drug development. Meanwhile, ELEO contributes its proprietary biological insights, which include advanced target validation techniques and screening platforms. These joint efforts aim to expedite the discovery and clinical validation of candidate therapies.

Dr. Kyungseop Ahn, CEO of ELEO, remarked on the collaboration, stating, "At ELEO, our discovery approach taps into the vast bioactive potential found in natural products. Our ongoing research has led to the identification of a promising PCSK9 inhibitor with a novel mechanism to combat hyperlipidemia. Our integration with Evogene's ChemPass AI™ empowers our efforts to produce the next generation of oral therapies for patients suffering from atherosclerosis."

Evogene's President and CEO, Ofer Haviv, added, "Joining forces with ELEO is an exceptional chance to apply our AI-driven technologies in a critical area of cardiovascular medicine. The combination of ELEO’s biological acumen and our computational capabilities establishes a powerful platform to design and refine small-molecule candidates that can potentially transform cardiovascular treatment landscape."

Future Prospects

With the aim of translating innovative research into viable clinical solutions, both companies will explore avenues for clinical development pathways and potential partnerships with pharmaceutical companies. The integration of advanced technology with biological expertise signifies a major step forward in addressing the pressing health challenges posed by cardiovascular diseases.

As they embark on this transformative journey, Evogene and ELEO demonstrate a commitment to leveraging innovation in improving healthcare outcomes worldwide. The integration of computational design with biopharmaceutical insights represents a promising future for the development of accessible and effective treatments, potentially expanding therapeutic options for millions of patients globally.

About the Companies

Evogene Ltd.

Evogene Ltd., listed on Nasdaq and TASE as EVGN, specializes in computational technologies aimed at the generative design of small molecules intended for both pharmaceutical and agricultural applications. At its core lies the ChemPass AI™, which helps in navigating extensive chemical spaces to yield potent small molecules tailored for drug development requirements.

ELEO Inc.

ELEO Inc., a South Korean biopharmaceutical firm, dedicatedly develops innovative oral therapeutics informed by natural product sciences. The company’s focus lies in advancing chronic disease treatments that meet substantial unmet medical needs, using a blend of in-depth pharmacological expertise and modern drug discovery methodologies.

Together, these two pioneering companies are paving the way for innovative solutions in the often challenging domain of cardiovascular health, promising not just enhanced treatment modalities but also better patient access and outcomes.